U.S. Markets closed

Peregrine Pharmaceuticals, Inc. (PPHM)


NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
0.573-0.01 (-1.53%)
At close: 4:00PM EDT
People also watch
THLDGALECTICXOMACYTR
  • According to the latest SEC filings they have to do the split by July 7 1017 and be in effect by July 21. So wont be long before we know what they are going to do
  • Sorry for the typo should be July 7 2017.
  • 7 shares this morning at .7482 are you kidding me?
  • (AXSM) Mcap $90 M /Cash $55 M / 5x Phase 3 programs in various indications targeting huge Markets with first results in Q3 2017 =10+ BAGGER .....Please read this below.......GLTA

    Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $90 million and $55 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .

    This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL

    Axsome (AXSM)

    Market-Cap: $90 Million
    Cash: $55 Million(cash runway into the first quarter of 2019.)
    Price:$3.90

    Shares Out: 23.5 Million

    Aegis Capital has reiterated a ‘Buy’ rating and price target of $20 on Axsome Therapeutics (NASDAQ: AXSM) after the company reported financial results for the quarter ended March 31, 2017. The analyst noted that although Axsome reported revenue in-line with consensus estimates, the focus remains on upcoming catalysts such as the company’s ongoing clinical trials. Since February 2017, the company’s AXS-05 has received fast track designation from the FDA for the treatment of Alzheimer’s disease (AD) agitation and treatment resistant depression (TRD). Topline data from the TRD treatment study is expected in the first quarter of 2018. Additionally, Axsome is developing AXS-02 in three separate phase 3 clinical programs, including chronic low back pain associated with modic changes and complex regional pain syndrome, with interim data expected in the fourth quarter of 2017, as well as knee osteoarthritis associated with bone marrow lesions, with interim data expected in the third quarter of 2017.
  • Even the lemmings are now dipping their little paw-like toes into the waters of joining in on the condemnation of the BOD. What these spineless followers don't understand is that in a bank heist, the wheelman is just as guilty as those inside carrying out the actual theft. Yet they give CloakedBODprotector and bioharm et al a pass.
    I don't.
  • You know when there's no joy in Humpsville after a long anticipated ASCO PR.
    bioharm and the deviant protector are nowhere to be seen,
    The mighty Casey has struck out again.
  • Visit the IHump Puzzle Brothers Escape Rooms. Puzzle Brothers Escape Rooms feature stories and environments that are truly original. Guests are challenged inside each room, where they team up with friends or family to solve puzzles tailored specifically for that narrative. The rooms emphasize out-of-the-box thinking and teamwork as teams work to solve codes and open locks before the money runs down to zero.
  • Cheyney - The most dangerous PP poster on social media.
  • MicroCap Alert to PPHM shareholders. Clean Energy Technologies, (CETY), trading at 2 pennies announced its acquisition of Heat Recovery Solutions assets, patents & licenses from General Electric (NYSE: GE)

    The Heat Recovery Solutions system captures waste heat from a variety of sources and turns it into electricity that users can use or sell back to the grid. There are currently more than 100 units installed by GE globally with more than 1,000,000 fleet operating hours. CETY sells each unit for $300,000.

    The conversion process requires no additional fuel, produces no additional emissions, and delivers base-load power that may be used on-site or sold to the grid.

    CETY recently announced they are establishing a Sales & Service Center in Europe.

    Demand for clean Heat Recovery Systems is enormous and shares could yield enormous percentage return on investment.
    http://www.prnewswire.com/news-releases/clean-energy-technologies-inc-delivering-low-cost-emission-free-power-with-its-heat-recovery-solutions-clean-cycle-generator-acquired-from-general-electric-international-inc-300228398.html

    Clean Energy Technologies, Inc. Delivering Low Cost, Emission Free Power with its Heat Recovery Solutions Clean Cycle™ Generator acquired from General Electric International, Inc.
    COSTA MESA, Calif., March 1, 2016 /PRNewswire/ -- Clean Energy Technologies, Inc. (OTC: CETY), recently...
    www.prnewswire.com
  • The questions that are ABSOLUTELY VERBOTEN - not even to be alluded to - on the Hump:
    WHAT IS BIOHARM'S AGENDA? WHY IS HE ALLOWED TO FREELY POST LIES WITH 100% PROTECTION FROM THE MODS? Why are posts calling him out on his 15+ years of being proven wrong immediately deleted?
  • Humper Gaddy reports 4 cent bump due to good news coming from ASCO poster this week end. Let's watch.
  • Now that Memorial Day's over is that TAPS i still hear playing for Peregrine Ponziceutical's stockholders or for this message board?
  • Remember Frank Hawkins? Reminds me of Amsterdam Boy and Bioflav.

    March 17, 2003

    Peregrine Names Steven King As President And Chief Executive Officer

    TUSTIN, Calif., Mar 17, 2003 /PRNewswire-FirstCall via COMTEX/ --

    Company Accepts Edward J. Legere's Resignation
    Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) announced today that Chief Operating Officer Steven King has been named president and chief executive officer. In addition to serving as chief operating officer, King has been serving as president and CEO of the company's wholly-owned subsidiary Avid Bioservices, Inc. Effective today, the company has accepted Edward J. Legere's resignation as president and CEO. Legere will work as a full time consultant during a three-month transition period and will remain a director of the company.

    "I am pleased that the board of directors had the confidence to name me as president and chief executive officer of Peregrine," said King. "I am very excited about the future of the company and look forward to executing the current business plan of licensing and early development work. We currently have active partnering discussions for all of our technologies with numerous biotechnology and pharmaceutical companies. Our Avid Bioservices subsidiary is making great strides in establishing itself as a biologics contract manufacturer. We look forward to the continued success of Avid and to successfully closing additional licensing agreements for our technologies. I would like to especially thank Ed for his tireless work over the past two years. I look forward to working with him over the next few months as I transition into my new position."

    "It is my great pleasure to see Steve King named president and CEO," said Legere. "Steve has worked extremely hard while at Peregrine and has earned the respect of everyone at the company. Over the past several years, Steve has been given increasing levels of responsibility. He has excelled as president and CEO of Avid and as COO of Peregrine. I look forward to assisting Steve in his transition from COO to CEO and feel he is extremely well prepared to accept this responsibility. It has been my pleasure serving as president and CEO of Peregrine over the past two years. In addition to assisting Steve with the transition, my main focus over the next three months will be to finalize the strategic initiatives set forth in our most recent quarterly report on Form 10-Q. I also look forward to continuing my service as a director of Peregrine, as I have done for so many years."

    King joined Peregrine as the director of research and development in 1997. He was promoted to vice president of technology and product development in 1999 where his duties were to direct the company's research and development activities, oversee and direct the patent strategy for the company's various technologies and participate in business development activities. In January 2002, King was named president and CEO of Avid Bioservices, Inc., the company's wholly-owned contract manufacturing subsidiary. King was responsible for setting up Avid as a biologics contract manufacturer and successfully launching the business. During this time, he also retained his duties as Peregrine's vice president of technology and product development. In September 2002, the board of directors promoted King to chief operating officer of Peregrine.

    King and Legere will host Peregrine's quarterly conference call on Tuesday, March 18th at 11:00 a.m. Eastern. In order to participate in this call, phone (877) 490-6982 at least five minutes before the call is scheduled to begin. International callers should dial (706) 679-0808.

    About Peregrine Pharmaceuticals

    Peregrine Pharmaceuticals is a biopharmaceutical company focused on the development, commercialization and licensing of unique technologies for the treatment of cancer, primarily based on three collateral targeting technologies. Peregrine's Tumor Necrosis Therapy (TNT), Vasopermeation Enhancement Agents (VEA), and Vascular Targeting Agents (VTA) technologies target cell structures and cell types that are common among solid tumor cancers, giving them broad applicability across various tumor types. The company has received approval from the FDA to start a Cotara™ Phase III clinical trial for brain cancer. Cotara is also being studied in a Phase I trial for colorectal, pancreas, soft tissue sarcoma and biliary cancers at Stanford University. The company is focused on licensing collaborations for all of its technologies under development. The company's Oncolym® technology to treat non-Hodgkin's B-cell lymphoma is in Phase I/II of development is available for licensing. The company also operates a cGMP contract manufacturing facility for monoclonal antibodies and recombinant proteins through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com). Copies of Peregrine press releases, SEC filings, current price quotes and other valuable information for investors may be found on the website www.peregrineinc.com. />
    Safe Harbor Statement: This release may contain certain forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ from the company's expectations as a result of risk factors discussed in Peregrine's reports on file with the U.S. Securities and Exchange Commission, including, but not limited to, the company's report on Form 10-K for the year ended April 30, 2002 and on Form 10-Q for the quarter ended January 31, 2003.

    Investor Relations Contact
    Frank Hawkins and Julie Marshall
    Hawk Associates, Inc.
    (800) 987-8256 or info@hawkassociates.com

    SOURCE Peregrine Pharmaceuticals

    CONTACT: Investor Relations, Frank Hawkins and Julie Marshall, both of
    Hawk Associates, Inc., +1-800-987-8256 or info@hawkassociates.com, for
    Peregrine Pharmaceuticals